Abstract: The present invention provides for a pharmaceutical composition comprising lenalidomide form A, a filler and a disintegrant and a superdisintegrant. The present invention further relates to a process for the preparation of said composition. The composition according to the invention may be used as medicament, particularly for the treatment of multiple myeloma and myeolodisplastic syndromes.

Abstract: The present invention is directed to crystalline vinorelbine monotartrate and its use for the prevention and treatment of cancer, particularly non-small cell lung cancer or breast cancer. The present invention also relates to a corresponding method for the manufacture of crystalline vinorelbine monotartrate.

Abstract: A delivery system for water-insoluble pharmaceutical active ingredients is provided. The delivery system includes water-insoluble pharmaceutical active ingredient(s), organic solvent(s) and amphiphilic co-solvent(s), and a mixture of hydrophilic and hydrophobic non-ionic surfactants. Upon dilution in an aqueous medium, this formulation forms spontaneously dispersion of non-ionic surfactant nanoparticles.

Abstract: This invention refers to pharmaceutical compositions that comprise the mixture of an effective amount of leucine-derivative powders or granules and, at least, one pharmaceutically acceptable excipient substance used as carrier. In particular, the main feature of the pharmaceutical composition is the fact that it is free of preservative agents and might be formulated in any usual pharmaceutical oral formulation.

Abstract: A method of increasing viscosity of a pharmaceutical formulation for oral or topical administration comprises the steps of combining: a. an effective amount of one or more hydrophobic active ingredients; b. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids of formula (1) CH2OR—CHOR—CH20-[CH2CHOR—CH2O—]NCH2—CHOR—CH2OR??(1) wherein n is an integer from 4 to 13 and R is H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen; c. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2) CH2OR—CHOR—CH20-[CH2CHOR—CH2O]NCH2—CHOR—CH2OR??(2) wherein n is an integer from 0 to 10 and R?H or CO.R? wherein R? is C8-22 saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen; d.

Abstract: Pharmaceutical compositions especially for internal application which create lyotropic liquid crystals when in contact with aqueous phase. The pharmaceutical compositions consist of: A hydrophobic active ingredient with immunomodulatory effect from a group of N-methylated cyclic undecapeptides or macrolide antibiotics, in quantity 1-35 weight % in a carrier medium containing B at least one absorption promoter allowing for contact of the drug with a biological membrane or passing of the drug through in quantity 1-40 weight %, C nonlipidic vehicle containing at lest one of the below mentioned substances: C1 surfactant or mixed surfactant with HLB>9, in quantity 1-80 weight % C2 lipophilic solvent from group of higher fatty alcohols in quantity 1-30 weight % C3 at least one cosurfactant in quantity 1-50 weight %, while a ratio among the individual components of the product is A:B:C=1:0.5-4:5-8.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Provided are therapeutic compositions which provide high bioavailability of the active ingredients from the group of cyclosporin, at the same time permitting concentrations in dosage forms higher than 10%.

Abstract: Therapeutical compositions comprising from 0.1 to 20% by weight of a cyclosporin and a vehicle comprising from 1 to 60% by weight of polyethers constituted by, preferably, substances like ethoxy diglycol or polyethylene glycols 300 to 600 and/or substances like preferably dimethyl isosorbide, dimethyl isoidide and dimethyl isomannide, and from 1 to 60% by weight of a mixture of glyceryl monoesters of C.sub.8 -C.sub.22 fatty acids and hexaglyceryl to pentadecaglyceryl monoesters of C.sub.8 -C.sub.22 fatty acids in a ratio of 1:2 to 1:6. The therapeutical compositions preferably additionally comprise further adjuvants like anti-oxidants, preserving agents and stabilizers, flavoring agents, thickening agents and diluents. The compositions for external use preferably additionally comprise lipoaminoacids.